

CLAIMS

1. Use of ifenprodil for the manufacture of a medicament for the treatment of pain.
2. Use according to claim 1, for the treatment of intermittent or episodic pain
- 5 experienced by a patient undergoing chronic pain treatment.
3. Use according to claims 1 or claim 2, wherein the pain is chronic benign pain.
4. Use according to claim 3, wherein the pain is related to a musculoskeletal, visceral or headache condition.
- 10 5. Use according to claim 4, wherein the condition is osteoarthritis, chronic pancreatitis or chronic migraine.
6. Use according to claim 2, wherein the pain is episodic or breakthrough pain in cancer.
7. Use according to claim 1, wherein the pain is acute pain.
- 15 8. Use according to claim 1, wherein the pain is post-operative pain.
9. Use according to any preceding claim, wherein the ifenprodil is in the form of either or both *threo* enantiomers.
10. Use according to claim 9, wherein the ifenprodil is (-)-*threo*-ifenprodil.
11. Use according to any preceding claim, wherein the medicament is for
- 20 administration via a route that avoids first-pass metabolism.
12. Use according to claim 11, wherein the route is sublingual.
13. Use according to claim 11, wherein the route is intranasal.
14. Use according to claim 11, wherein the route is dermal.
15. Use according to any of claims 11 to 14, wherein the medicament is in the
- 25 form of a unit dosage containing less than 60 mg ifenprodil.
16. A composition suitable for intranasal delivery, which comprises an aqueous solution of ifenprodil, a solubility enhancer and a humectant.
17. A composition according to claim 16, wherein the ifenprodil is (-)-*threo*-ifenprodil.
- 30 18. A composition according to claim 17, wherein the ifenprodil is (-)-*erythro*-ifenprodil.